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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S439To explore this, the aim of this study was to evaluate the impact of a FR
program on the variation in muscle/lean mass and fat mass in patients
with chronic low back pain.
Patients and methods: Design: longitudinal uncontrolled French
monocentric prospective study. Patients: All patients with chronic low
back pain who participated in the FR program between January 2010
and March 2013 where included. Intervention: The FR program was
carried out over a period of 4 weeks, 5 days aweek and included 3 hours
per day of intensive physical training as well as patient education,
relaxation etc through a multidisciplinary approach. Assessment: DXA
was performed at baseline, at 1 month (end of the FR program) and at 6
months. The primary endpoint was the absolute variation in the muscle
mass (or lean mass) calculated by DXA between baseline and 6 months.
Variations in fat mass and variations as 1 month were also analysed.
Statistical analysis: parametric paired tests (student’s t) and non-
parametric paired test (Wilcoxon) in the total population and based on
the body mass index (BMI) at inclusion : normal weight versus over-
weight or obesity (BMI>25kg /m2). Only patients with DXA available at
baseline and 6 months were included in the analyses (no imputation of
missing data).
Results: In all, 95 patients were included, 40 men and 55 women: mean
age 41 (8.4) years, mean BMI 26.6kg/m2, 38 (60%) where overweight
or obese. At 1 month, there was an increase in lean mass (mean change
þ1.3kg) and a decrease in fat mass (mean change -0.6kg) in the total
population and in the subgroups according to BMI (p all <0.05). At 6
months, the increase in lean mass (mean change þ0.3kg versus base-
line) was only signiﬁcant in the subgroup of patients who were over-
weight or obese (p¼ 0.03 and p¼ 0.04 respectively versus baseline) and
there was no signiﬁcant decrease in fat mass compared to baseline.
Conclusion: A FR program improves muscle mass in the short term in
chronic low back pain patients but this gain is lost 6 months after the
program. There results suggest that FR programs are not just a “ﬁtness
class” and that the beneﬁts of FR programs can also probably be
attributed to patients’ education and coping, as enhanced during the
program. Further studies are needed onmechanisms improving chronic
low back pain.Stem / Progenitor Cells
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Purpose: Synovial mesenchymal cells (SMCs) can be expanded in cul-
ture and differentiate into diverse cell lineages. The extracellular
“niche” microenvironment plays an important role in the proliferation
and differentiation of mesenchymal stem cells. Despite the current
clinical application of SMCs, the molecular mechanisms underlying the
multi-potentiality of SMCs remain unclear. To address these mecha-
nisms, we established a primary mouse synovial cell culture method, in
which mouse SMCs demonstrated both the ability to proliferate and
multi-potentiality. Perlecan, a heparan sulfate proteoglycan, is impli-
cated in cell growth, differentiation, signaling, and stem cell main-
tenance. The purpose of the present study was to investigate the role of
perlecan during chondrogenic, osteogenic and adipogenic differ-
entiation from SMCs.
Methods: The primary SMCs were isolated by our established method
from ten-week old female Hspg2-/--Tg in which perlecan was absent in
the SMCs. We used control cells from Hspg2þ/þ-Tg mice. We analyzed
the growth kinetics and expression of the cell surface antibodies using
ﬂow cytometry (FACS). We evaluated the chondrogenic potential of
SMCs in micromass cultures by both Alcian blue staining and quanti-
tative real-time PCR (qRT-PCR) analysis of total RNA isolated at 3, 12, 72
hours, 1 and 2 weeks after chondrogenic induction. In a rescueexperiment, recombinant perlecan at 0.1, 1, or 10 mg/ml was added to
both the micromass cultures and chondrogenesis culture medium, and
Sox9 mRNAwas assayed after 3 hours. To evaluate osteogenic potential,
SMCs were cultured in osteogenic medium and colonies stained with
fresh 0.5% alizarin red solution were counted, followed by staining with
crystal violet and colony counting. To evaluate adipogenesis, SMCs were
cultured in adipogenic medium and colonies stained with fresh 0.5% oil
red O solution were counted, followed by staining with crystal violet
and colony counting. We also evaluated the osteogenic and adipogenic
potential of SMCs by qRT-PCR at 3 hours after osteogenic and adipo-
genic induction, respectively.
Results: Primary mouse SMCs isolated from knee joints of control mice
expressed perlecan, while those from Hspg2-/--Tg mice did not, as
assessed by both immunohistochemical and qRT-PCR analyses. The
SMCs cultures from control and Hspg2-/--Tg mice showed similar pro-
liferative potential and expression of the cell surface antibodies (CD29,
CD34, CD44, CD106, Sca-1 and CD140a) using FACS. However, during in
vitro chondrogenic induction in micromass culture, the cartilage matrix
production detected by Alcian blue staining was dramatically inhibited
in perlecan-deﬁcient SMCs, but not in control SMCs (p< 0.05). The qRT-
PCR analysis also demonstrated that the levels of Sox5, Sox9 and Col2a1
mRNAs were reduced during chondrogenic induction in perlecan-
deﬁcient compared to control SMCs (p < 0.05). When perlecan was
added to micromass and chondrogenic culture medium in perlecan-
deﬁcient SMCs, Sox9 mRNA was restored to levels assayed in control
SMCs. During in vitro osteogenic induction, the levels of Col1a1, Runx2,
osteocalcin, and osteopontin mRNA were similar in perlecan-deﬁcient
and control SMCs. The numbers of alizarin red-positive colonies after
osteogenic inductionwere also similar in perlecan-deﬁcient and control
SMCs. During in vitro adipogenic induction, the levels of PPARg mRNA
and oil red O-positive colonies were signiﬁcantly reduced in perlecan-
deﬁcient compared to control SMCs (p < 0.05).
Conclusions: This in vitro study showed that SMCs were viable and
proliferative, even in the absence of perlecan. Osteogenic inductionwas
not affected by the absence of perlecan. On the other hand, when SMCs
were induced to undergo chondrogenesis or adipogenesis, matrix
production and chondrogenic or adipogenic gene expression were
impaired by the absence of perlecan. Therefore, perlecan in the synovial
niche is a prerequisite for chondrogenic and adipogenic, but not
osteogenic, differentiation of SMCs.
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Purpose: The goal of this study is to dissect the molecular pathogenesis
of Campomelic Dysplasia (CD), a skeletal malformation disease caused
by heterozygous mutations affecting SOX9 expression. Since access to
embryonic cartilage tissue is not feasible and various mutations can
result in different phenotypic outcomes, induced pluripotent stem cells
(iPSCs) were generated from two different CD patients and differ-
entiated in vitro and in vivo towards chondroprogenitors and cartilage
tissue, respectively.
Methods: Patient ﬁbroblasts were obtained from two CD patients
encoded by different SOX9 mutations (referred to as CD short and CD
long) as well as two healthy, gender-matched donor controls (WT
iPSCs). Fibroblasts were reprogrammed to iPSCs through retroviral
overexpression of OCT4, SOX2, KLF4, and C-MYC. Three iPSC clones from
each CD patient and two clones from each healthy control were char-
acterized and used in this study. Molecular differences between CD and
WT iPSCs were identiﬁed through in vitro and in vivo differentiation
methods. For in vitro methods, iPSCs were ﬁrst differentiated towards
mesendoderm fate using a combination of BMP4 and Activin A. Cells
were further differentiated towards chondroprogenitors using a
micromass culture approach. For in vivo methods, iPSCs were injected
intramuscularly into immunodeﬁcient mice. Teratomas formed 12-16
weeks later and cartilage tissues generated within the teratomas were
analyzed and compared.
Results: iPSCs were successfully generated from CD patient ﬁbroblast
samples. All clones expressed human embryonic stem cell surface
